Genital Diseases, Female  >>  sorafenib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sorafenib / Generic mfg.
NCT00096395: Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

Completed
2
33
Canada
gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
02/07
 
NCT00522301: Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Terminated
2
6
US
sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Bayer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
03/08
03/08
NCT00238121: Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Completed
2
56
US, Canada
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN
National Cancer Institute (NCI)
Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma
07/10
07/10
NCT00245102: Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Completed
2
147
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN
National Cancer Institute (NCI)
Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
03/11
03/11
NCT00791778 / 2008-004429-41: Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Checkmark Maintenance therapy in front line ovarian cancer
Apr 2013 - Apr 2013: Maintenance therapy in front line ovarian cancer
Completed
2
246
Japan, US, Canada, Europe, RoW
Sorafenib (Nexavar, BAY43-9006), Placebo
Bayer
Ovarian Neoplasms
07/11
12/12
NCT00390611: Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Completed
2
85
US
Sorafenib, BAY 43-9006, Paclitaxel, Carboplatin
SCRI Development Innovations, LLC, Bayer
Ovarian Cancer
07/12
04/14
TRIAS 2009, NCT01047891 / 2009-011922-33: Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
2
174
Europe
Sorafenib, Nexavar®
JSehouli
Ovarian Cancer
02/15
02/15
NCT00526799: Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Terminated
1/2
30
US
Sorafenib, Topotecan
Daniela Matei, MD, Bayer, Hoosier Cancer Research Network
Ovarian Cancer
01/10
08/10
NCT00510250: A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Completed
1/2
13
Canada
Sorafenib, Cisplatin, Radiation
University Health Network, Toronto, Bayer
Cancer of the Cervix
09/10
07/15

Download Options